Nevertheless, other studies reported that plerixafor (either with G-CSF alone or in association with chemotherapy) elicits a lower rate of collection of sufficient transplant doses and lower CD34+ cell yield in patients with non-Hodgkin lymphoma compared to patients with either MM or HL [27,28,29,39]. The gene discussed is CSF3; the disease is Miyoshi myopathy.